http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H04159233-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c999fee6428152a996011d506925c2d7 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 |
| filingDate | 1990-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48530ced690d14e57c3f9a3c98c8ff8a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_132a36c4da73209145f3f58b78c6e6b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63424261ee4d02e3296e5008696bd126 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_361dfda65a8f48abfc5c6cfb50d98e06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4914f2480f59db72921efd9455a8a5f0 |
| publicationDate | 1992-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H04159233-A |
| titleOfInvention | Red blood cell-hematopoietics |
| abstract | PURPOSE: To obtain the subject red blood cell-hematopoietics useful for improvement of an anemia state especially during application of a chemotherapeutic agent in a cancer-carrying state by using an immunostimulant in combination with erythropoietin. n CONSTITUTION: An objective drug is obtained by using an immunostimulant, e.g. lenthinan, picibanil and kurestin, especially lenthinan belonging to neutral polysaccharide, having no direct toxicity to cells and excellent in an activation effect on biophylaxis function in combination with erythropoietin(EPO). The immunostimulant remarkably increases EPO-sensitive precursor cells for red blood cell-hematopoiesis and the anemia state is improved by an effect of EPO on the above-mentioned precursor cells. As the dosage form, a simple drug form containing both the components is recommendably used and separate administration of both the components is also recommendable. A parenteral drug, especially an injection composed of an isotonic aqueous solution or suspension is suitable in general. n COPYRIGHT: (C)1992,JPO&Japio |
| priorityDate | 1990-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.